Stockprowler picks NNLX for January 2008
As the value of the dollar continues to plummet in the world market,
watch for the price of oil to reach unthinkable levels. You think $100 a
barrel oil is bad and just a temporary aberration? Look for $150 a barrel
oil by July 2008 as the Arabs demand more worth-less U.S. dollars for their oil.
And as oil becomes a more and more expensive source of energy, other fuel
alternatives become viable. In the Stockprowler crystal ball we see hydrogen
eventually replacing oil as the primary source of energy in our increasingly
energy hungry world. Hydrogen is the most abundant element in the universe and
also has the highest energy content per unit weight of any known fuel.
The bad news is that it rarely occurs by itself in nature. It
is mostly found combined with other elements from which it must be
separated. The good news is that once extracted, hydrogen in liquid
form is the ultimate clean and highly compacted energy carrier. Presently,
the cost of commercially generating hydrogen is almost $5.00 per equivalent
gallon of gasoline.
Enter NanoLogix (OTC: NNLX) trading at around 10 cents.
NanoLogix has patented technology to inexpensively produce
hydrogen from biomass. It is rumored that its commercial process
can deliver hydrogen at less than $1.00 per equivalent gallon of
gasoline. NanoLogix is presently operating a hydrogen bioreactor
at Welch's Foods near Erie, Pennsylvania to produce hydrogen from
Welch's sugar-rich wastewater stream. R&D into a next-generation
commercial demonstration bioreactor for Welch's is ongoing at Gannon
University in Erie. This effort has been solely funded by NanoLogix
for the prototype bioreactor development, with major funding from Welch's
anticipated for the next stage. NanoLogix has signed an agreement with the
City of Erie Wastewater Treatment Plant for a prototype bioreactor
installation based upon NanoLogix's patents and designed to extract
hydrogen from activated sewage sludge. The Company's goal is to
capitalize on the potential energy value of over 170 million tons
of sewer sludge generated annually in the United States. NanoLogix
plans to install the prototype in the Erie facility in the spring of 2008.
NanoLogix has 31 granted patents and 36 patents pending for bioreactor-based
hydrogen production, revolutionary rapid medical testing technologies, potential
treatments for sepsis and cancer, and bioremediation. NanoLogix has also filed 7
patents for its new BioNanoChannel™ technology for rapid microorganism
(bacteria/spores) detection and identification. This is a revolutionary,
cutting-edge technology developed by NanoLogix that enables the identification
and/or growth of microorganism cultures in 1 to 7 hours. BioNanoChannel™ technology
utilizes extremely small nano-sized channels to trap microorganisms and then
applies proprietary NanoLogix techniques covered in the patent to detect and/or
identify the microorganisms in concentrations as small as a single cell.
This technology is in sharp contrast to the traditional
method for detection and growth utilizing Petri dishes --- a device
invented in 1877 --- a process that normally takes 24 to 72 hours to
identify or culture a microorganism. The importance of this is that in
a critical infection situation, the ability to achieve rapid detection
and identification of microorganisms can mean the difference between life
and death. NanoLogix believes that BioNanoChannel™ technology has the
potential to capture much of the current global multi-billion dollar Petri
dish market.
The company is in talks with the US Department of Defense for providing of
BioNanoChannel technology for use in the confirmation of effectiveness of
decontamination efforts in the event of biological attacks, currently specific
to anthrax, but with the potential for use in the event of use of other biological
agents or toxins. NanoLogix has been contacted by an international pharmaceutical
company and asked to provide information and assistance in reducing the time to test
pharmaceutical samples to less than 24 hours --- a task that is easily within the
capabilities of the BioNanoChannel technology.
NanoLogix is currently working with another unnamed company to ascertain
whether a BioNanoChannel device can provide a method for reducing the time
necessary for the identification and detection of protein markers that occur
early on in victims of Traumatic Brain Injury (TBI). Public attention has
recently focused on TBI due to the publicity received by returning veterans
from both Afghanistan and Iraq who have been exposed to various types of
blast injuries from Improvised Explosive Devices (IED). In fact, it is a
condition that affects over 1,500,000 victims of accidents and violence each
year in the United States alone. The research team's initial findings have been
positive. Earlier detection of these protein markers may lead to accelerated
treatment and reduced long term negative effects on those who suffer from these
potentially debilitating injuries.
NanoLogix has the near-term potential to capitalize on its rapid-detection
technology, as evidenced by recent and ongoing government and corporate
interest. There is longer term potential for revenue from both the hydrogen
bioreactor technology use in industrial and wastewater treatment plant
settings, and in sales of medical and environmental test kit technology
through NutraPharma Corp. Nutra Pharma Corp. (OTCBB: NPHC) is a biotechnology
company that is developing drugs for HIV and Multiple Sclerosis (MS),
and recently announced that it has expanded its licensing agreement with
NanoLogix, Inc.
NanoLogix has submitted international patent applications for
BioNanoChannel™ and Hydrogen Bioreactor technology protection in China,
India, Brazil, and the EU (European Union). These filings are in anticipation
of the global roll-out of the company's rapid BioNanoChannel™ bacteria/microorganism
detection technology and also contribute to the protection of NanoLogix's ongoing
Hydrogen Bioreactor development.
Further information on NanoLogix, Inc. is available at
www.nanologixinc.com
Well, all right,
that's it for now… place your bets, sit back and relax. Remember, this is speculation not
investing and quite often we get rewarded BIG for taking a chance…
Stockprowler.com does not receive compensation from companies we profile or
from third parties... we never have and never will. We use our own money
when we buy stocks, and even though we usually take a position in a stock
before we profile a company, our purchases are small relative to the public
float so that the effect on the stock price when we buy or sell is minimal.
Please read our full disclaimer.
Also, contrary to a commonly held belief, Stockprowler does not have access
to insider information, nor do we want to because trading on insider
information is illegal! All information contained in our reports is
available in the public record... and any written or verbal communication
with company CEOs/IR people strictly adheres to this rule.
Readers are urged to read the company SEC filings and do their own due
diligence before investing in this or any other stock.
Good Trading... Stockprowler.
